Calculated fast-growing benign prostatic hyperplasia - A risk factor for developing clinical prostate cancer

Scandinavian Journal of Urology and Nephrology

Volumn 36, Issue 5, 2002, Pages 330-338

  Hammarsten, Jan ^a   Högstedt, Benkt ^b  

^a VARBERG HOSPITAL   (Sweden)

^b HALMSTAD HOSPITAL   (Sweden)

Author keywords

Benign prostatic hyperplasia; Dyslipidaemia; Hyperinsulinaemia; Hypertension; Metabolic syndrome; Non insulin dependent diabetes mellitus; Obesity; Prostate cancer; Prostate specific antigen

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY BUILD; BODY MASS; BODY WEIGHT; CANCER GROWTH; CANCER RISK; CANCER STAGING; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSLIPIDEMIA; HUMAN; HUMAN TISSUE; HYPERINSULINEMIA; HYPERTENSION; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RISK FACTOR;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; BLOOD CHEMICAL ANALYSIS; BODY MASS INDEX; CASE-CONTROL STUDIES; COHORT STUDIES; COMORBIDITY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; PRECANCEROUS CONDITIONS; PROBABILITY; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REFERENCE VALUES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; SWEDEN; TRANSURETHRAL RESECTION OF PROSTATE;

EID: 0036434102     PISSN: 00365599     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655902320783827     Document Type: Article

References (29)

1. th International Consultation on Benign Prostatic Hyperplasia (BPH), Proceedings 4. Plymebridge Distributors Ltd, Plymouth, United Kingdom, 1998.
2. Kirby R, Christmas T, Brawer M. Chapter 3. In: Prostate Cancer, Mosby, an imprint of Times Mirror International Publishers Limited, 1996.
3. McNeal J. Pathology of benign prostatic hyperplasia. Urol. Clin. N. Am. 1990; 17: 477-86.
4. Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, et al. Latent carcinoma of the prostate at autopsy in seven areas. Int. J. Cancer 1977; 20: 680-8.
5. Armenian HK, Lilenfeld AM, Diamond EL, Bross IDJ. Relation between benign prostatic hyperplasia and cancer of the prostate. Lancet 1974; 2: 115-17.
6. Tiblin G. Prostatic cancer: the men born in 1913 study. In: Medical Products Agency: Workshop: Pharmacological Treatment of Prostatic Cancer, Vol. 3. Uppsala, Sweden: Medical Products Agency. 1993: 13-9.
7. Greenwald P, Kirmss V, Polan AK, Dick VS. Cancer of the prostate among men with benign prostatic hyperplasia. J. Natl. Cancer Inst. 1974; 53: 335-40.
8. Hammarsten J, Andersson S, Holmén A, Högstedt B, Peeker R. Does transurethral resection of a clinically benign prostate gland increase the risk of developing clinical prostate cancer? A 10-year follow-up study. Cancer 1994; 74: 2347-51.
9. Lund K, Ewertz M, Schou G. Breast cancer incidence subsequent to surgical reduction of the female breast. Scand. J. Plast. Reconstr. Surg. 1987; 21: 209-12.
10. Mostofi FK, Sesterhenn I, Sobin LH. Histological typing of prostate tumours, International Histological Classification of Tumors No. 22, WHO, Geneva, 1980.
11. Schröder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate Suppl. 1992; 4: 129-38.
12. Littrup PJ, Williams CR, Egglin TK, Kane RA. Determination of prostate volume with transrectal US for cancer screening - Part II. Accuracy of in vitro and in vivo techniques. Radiology 1991; 179: 49-53.
13. Terris MK, Stamey TA. Determination of prostate volume by transrectal ultrasound. J. Urol. 1991; 145: 984-7.
14. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J. Urol. 1984; 132: 474-9.
15. Gay JM. Clinical epidemiology and evidence-based medicine glossary. In: Terminology Specific to Epidemiology, updated August 22, 1999, page 2 http://www.vetmed.wsu.edu./courses-jmgay/GlossEpiTerminology.htm
16. Hammarsten J, Högstedt B, Holthuis N, Mellström D. Components of the metabolic syndrome - Risk factors for the development of benign prostatic hyperplasia. Prostate Cancer and Prostatic Diseases 1998; 1: 157-62.
17. Hammarsten J, Högstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Pressure 1999; 8: 29-36.
18. Hammarsten J, Högstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. European Urology 2001; 39: 151-8.
19. Reavan GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
20. Rett K, Wicklmayr M, Mehnert H. New aspects of insulin resistance in hypertension. European Heart Journal 1994; 15 (Supplement C): 78-81.
21. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-94.
22. Krotkiewski M. Role of muscle capillarization and morphology in the development of insulin resistance and metabolic syndrome. Presse Med. 1994; 23: 1353-6.
23. Timar O, Sestier F, Levy E. Metabolic syndrome X: A review. Can. J. Cardiol. 2000; 16: 779-89.
24. Lithell H. In: Insulinresistens. En bas för Förståelsen av Kardiovaskulära Sjukdomars Etiologi och Behandling. Bristol-Myers Squibb AB 1992.
25. Gleason DF. Histologic grading of prostate cancer: A perspective. Human Pathology 1992; 23: 273-9.
26. Morton MS, Blacklock N, Denis L, Griffiths K. Western diet and prostate cancer: does the available evidence justify dietary advice. In: Schröder FH. Recent Advances in Prostate Cancer and BPH. New York: The Parthenon Publishing Group Inc., 1996: 61-74.
27. Kalkhoff RK, Kim HJ, Cerletty J, Ferrou CA. Metabolic effects of weight loss in obese subjects. Changes in plasma substrate levels, insulin and growth hormone responses. Diabetes 1971; 20: 83-91.
28. Nilsson PM, Lindholm LH, Scherstén BF. Life style changes improve insulin resistance in hyperinsulinaemic subjects: A one-year intervention study of hypertensives and normotensives in Dalby. J. Hypertens. 1992; 10: 1071-78.
29. Jimenez J, Zuniga-Guajardo S, Zinman B, Angel A. Effects of weight loss in massive obesity on insulin and c-peptide dynamics: Sequential changes in insulin production, clearance, and sensitivity. Endocrinol Metab. 1987; 64: 661-8.